Anti-PD-L1 monoclonal antibody shows promise in lung cancer patients
In a Phase III trial sugemalimab meaningfully improved progression free…
In a Phase III trial sugemalimab meaningfully improved progression free survival in patients with stage III non-small cell lung cancer (NSCLC).